Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Armuzzi

Showing results (211-220 of 320) with videos related to

Pageof 32
Sort By:
World Journal of Gastroenterology|January 23, 2023
Artificial intelligence and inflammatory bowel disease: Where are we going?Leonardo Da Rio, Marco Spadaccini, Tommaso Lorenzo Parigi, et al.
Reumatismo|November 11, 2024
The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel diseaseEnnio Lubrano, Alessandro Armuzzi, Silvia Scriffignano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 14, 2021
Female reproductive health and inflammatory bowel disease: A practice-based review, Alessandro Armuzzi, Aurora Bortoli, et al.
Journal of Crohn'S & Colitis|July 17, 2020
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel DiseaseGiuseppe Privitera, Sara Onali, Daniela Pugliese, et al.
Journal of Personalized Medicine|May 25, 2024
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative ColitisLucrezia Laterza, Anna Chiara Piscaglia, Stefano Bibbò, et al.
Journal of Crohn'S & Colitis|January 30, 2014
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomyRita Monterubbianesi, Annalisa Aratari, Alessandro Armuzzi, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|June 7, 2026
Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter studyFerdinando D'Amico, Fabrizio Fanizzi, Arianna Dal Buono, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Pageof 32

Showing results (211-220 of 320) with videos related to

Sort By:
Pageof 32
World Journal of Gastroenterology|January 23, 2023
Artificial intelligence and inflammatory bowel disease: Where are we going?Leonardo Da Rio, Marco Spadaccini, Tommaso Lorenzo Parigi, et al.
Reumatismo|November 11, 2024
The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel diseaseEnnio Lubrano, Alessandro Armuzzi, Silvia Scriffignano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 14, 2021
Female reproductive health and inflammatory bowel disease: A practice-based review, Alessandro Armuzzi, Aurora Bortoli, et al.
Journal of Crohn'S & Colitis|July 17, 2020
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel DiseaseGiuseppe Privitera, Sara Onali, Daniela Pugliese, et al.
Journal of Personalized Medicine|May 25, 2024
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative ColitisLucrezia Laterza, Anna Chiara Piscaglia, Stefano Bibbò, et al.
Journal of Crohn'S & Colitis|January 30, 2014
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomyRita Monterubbianesi, Annalisa Aratari, Alessandro Armuzzi, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|June 7, 2026
Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter studyFerdinando D'Amico, Fabrizio Fanizzi, Arianna Dal Buono, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Pageof 32